Andres Eduardo N. O.
- Country
- Spain
- Department
- Neuropediatrics
Research Overview
- Phase 3 Study of Delpacibart Zotadirsen in Duchenne Muscular Dystrophy with Mutations Amenable to Exon 44 Skipping
- Evaluation of Satralizumab Efficacy and Safety in Pediatric Duchenne Muscular Dystrophy: A Phase II Multicenter, Open-Label Study
- Safety and Tolerability Assessment of BMN 351 in Duchenne Muscular Dystrophy: A Phase 1/2 Dose Escalation Study
Data & Insights
Has run more than one trial at 7 of 22 partner sites.
Specializations
Duchenne Muscular Dystrophy Research
Primary focus on developing therapeutic approaches for Duchenne muscular dystrophy (DMD), with particular emphasis on gene transfer therapy and exon skipping treatments. The investigator explores various therapeutic compounds including delandistrogene moxeparvovec, eteplirsen, and vesleteplirsen.
- Gene Transfer Therapies
- Exon Skipping Treatments
- Motor Function Assessment
Neuromuscular Disorders
Extensive work in treating various neuromuscular conditions, including Spinal Muscular Atrophy (SMA) and Generalized Myasthenia Gravis. Research involves evaluating novel therapeutic agents such as apitegromab, nusinersen, and efgartigimod.
- SMA Treatment Development
- Myasthenia Gravis Therapies
- Long-term Safety Studies
Rare Genetic Disorders
Investigation of treatments for rare genetic conditions including Thymidine Kinase 2 deficiency and Glycogen Storage Disease Type II. Focus on evaluating combination therapies and enzyme replacement treatments.
- Metabolic Disorders
- Enzyme Replacement Therapy
- Pyrimidine Nucleoside Studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.